Follow us on Twitter
This page is updated frequently with new Autoimmune-related patents. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds.
Subscribe to updates on this page: Autoimmune RSS
|| List of recent Autoimmune-related patents
| Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake.
| Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases|
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
| Methods and compositions for the treatment of cancer or other diseases|
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
| Utilization of dialkylfumarates|
The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines..
| Treatment of diseases associated with inflammation|
Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e.g. Hydroxychloroquine, and a statin, e.g.
| Substituted benzoazepines as toll-like receptor modulators|
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease..
| S1p receptors modulators and their use thereof|
The invention relates to novel compounds that have sip receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate sip receptor modulating activity or expression, for example, autoimmune response.
| Steroid compounds as roryt modulators and uses thereof|
And wherein m, n, t, u1, u2, v1, v2, r1a, r1b, r2a, r2b, r3a, r3b, r3c, r3d, and y are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the treatment or prevention of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease..
| Peptides and methods for inducing cell death|
The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein.
| Antibody with specificity for gm-csf (ii)|
The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (gm-csf). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human gm-csf with high affinity.
| Tlr3 binding agents|
The invention provides anti-tlr3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-tlr3 antibodies..
| Therapeutic use of anti-cs1 antibodies|
The present invention is directed to antagonists of cs1 that bind to and neutralize at least one biological activity of cs1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof.
|Ideotypically modulated pharmacoeffectors for selective cell treatment|
In a method embodiment, a method includes introducing a plurality of ideotypically modulated pharmacoeffectors (imp) into a population of cells. Each imp may include a detection domain and an activation domain.
|Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo|
The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat type i diabetes.
|Immunomodulation by controlling interferon-gamma levels with the long non-coding rna nest|
Compositions and methods of modulating an immune response by controlling levels of interferon-gamma (ifn-γ) production by leukocytes are disclosed. Adjustment of ifn-γ levels is achieved by increasing or decreasing the activity of nest (nettoie salmonella pas theiler's [cleanup salmonella not theiler's]), a long non-coding rna that induces expression of ifn-γ.
|Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death|
Disclosed herein are methods and compositions comprising fingolimod and anti-cd74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of cd74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-cd74 antibodies.
|Anti-cd19 antibodies and uses in b cell disorders|
The invention relates to immunotherapeutic compositions and methods for the treatment of b cell diseases and disorders in human subjects, such as, but not limited to, b cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human cd19 antigen and that preferably mediate human adcc. The present invention relates to pharmaceutical compositions comprising human or humanized anti-cd19 antibodies of the igg1 or igg3 human isotype.
|Vista-ig for treatment of autoimmune, allergic and inflammatory disorders|
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig). The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions..
|Compositions and method for treating autoimmune diseases|
The invention provides methods and compositions for treating various autoimmune diseases (such as systemic lupus erythematousu) with an interferon inhibitor (such as an anti-intereron-alpha monoclonal antibody). More specifically, the invention provides a method of diagnosing, monitoring and adjusting the treatment of such a patient by way of an interferon signature metric (interferon response gene measurement value), a certain anti-dsdna antibody titre or being ena− (levels of extractable nuclear antigens lower than a healthy level).
The present invention relates to crystalline forms and hydrates of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.. .
|Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use|
Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .
|Mst1 kinase inhibitors and methods of their use|
Compounds for the inhibition of mammalian ste20-like kinase 1 (mst1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.. .
|Novel compound useful for the treatment of degenerative and inflammatory diseases|
Novel pyrrazolopyridines according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .
|Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds|
Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment.
|Method of treating transplant rejection and autoimmune diseases|
A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of su-5416 is disclosed.. .
|T-cell redirecting bispecific antibodies for treatment of disease|
The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
|Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use|
The invention relates, in part, to antibodies with increased adcc activity. Methods of producing such antibodies are also provided.
|Gene therapy compositions for preventing and/or treating of autoimmune diseases|
Gene therapy compositions for the prevention and/or treatment of autoimmune diseases. The present invention relates to vectors, preferably plasmids that comprise specific promoters, that encode insulin-like growth factor i (igf-i) or a functional biological equivalent thereof, which will be used to prevent or treat type 1 diabetes (dt1) and/or other autoimmune diseases.
|Neutralizing anti-ccl20 antibodies|
The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human cc chemokine ligand 20 (ccl20). The present invention further relates to heavy chains and light chains of said antibodies.
|Biomarkers used to detect and monitor neurological autoimmune diseases|
Biomarkers of neurological autoimmune diseases are described, and methods of using such biomarkers also are described.. .
Popular terms: [SEARCH]
Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence
Follow us on Twitter
This listing is a sample listing of patents related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.